Journey Medical Corporation Recaps 2019 Growth
Fortress Biotech, Inc. (FBIO)
Last fortress biotech, inc. earnings: 11/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
fortressbiotech.com
Company Research
Source: GlobeNewswire
Potent sales and marketing model drives continued commercial success of branded dermatology products Preliminary unaudited full-year 2019 net revenue expected to be between $33 million and $36 million SCOTTSDALE, Ariz., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Journey Medical Corporation today announced an update on its growth and business performance, including preliminary unaudited fourth quarter and full-year 2019 net revenue. “2019 was a banner year for us,” said Claude Maraoui, president and chief executive officer of Journey Medical. “Our model of licensing or acquiring dermatology assets that strategically fit our company continues to fuel our long-term growth. In the past year, we acquired and launched Ximino®, a prescription oral antibiotic indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris, and expanded our sales force to 41 sales representatives who are dedicated to promoting our products, including Targadox® and Exelderm®.” As a pa
Show less
Read more
Impact Snapshot
Event Time:
FBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBIO alerts
High impacting Fortress Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
FBIO
News
- Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Fortress Biotech, Inc. (NASDAQ: FBIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Fortress Biotech, Inc. (NASDAQ: FBIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire
FBIO
Earnings
- 11/14/23 - Beat
FBIO
Sec Filings
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- 4/5/24 - Form 424B3
- FBIO's page on the SEC website